相关实验视频

Updated: Jan 17, 2026

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease

Published on: August 18, 2023

达奇可以通过抑制5HT途径介导的PANoptosis和改善代谢异常来缓解便秘

Meiyu Wan¹, Tiexin Sun¹, Yuying Diao¹

¹Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, PR China.

Journal of ethnopharmacology

|January 14, 2026

概括

达奇 (DCQ) 通过调节血清素 (5-HT) 途径,减少炎症和恢复代谢平衡,有效治疗便秘. 这项研究阐明了DCQ的便秘缓解机制.

科学领域:

药理学药理学是指药理学的学科.
代谢学代谢学代谢学
传统中国医药传统中国医药

背景情况:

达奇 (DCQ) 是一种传统中医药 (TCM) 配方,在治疗便秘方面有着悠久的使用历史.
在缓解便秘方面DCQ的有效性背后的精确药理机制尚未完全理解.

研究的目的:

系统地阐明DCQ在缓解便秘中的生物活性成分,关键目标和潜在机制.
整合网络药理学,代谢学,分子对接和实验验证,以全面理解.

主要方法:

利用网络药理方法来预测治疗途径.
建立了洛佩拉胺诱导的便秘大鼠模型,用于体内验证.
使用UPLC-Q-TOF-MS/MS进行血和尿液的代谢分析.
通过分子对接,基于细胞的测定和基因/蛋白质表达分析验证了关键途径目标 (例如,5-HT,PLA2,cAMP/PKA/AQPs,PANoptosis).

主要成果:

在大鼠模型和Caco-2细胞中,DCQ改善了便秘症状并减少了炎症.
代谢分析显示DCQ正常化异常血和尿路代谢概况.
综合分析确定了血清素 (5-HT) 途径是中心的,涉及抑制PLA2介导的炎症和PANoptosis,并激活cAMP-PKA-AQPs级联.

结论:

通过激活5-HT通路,DCQ恢复了代谢平衡,并减轻了炎症.
DCQ的机制可能涉及肠道上皮细胞中与PANoptosis相关的途径的调节.
这些发现为使用DCQ治疗便秘提供了新的视角.

关键词:

5HT通道的5HT通道达基的蒸达基的蒸这就是PANoptosis.便秘便秘便秘便秘代谢生物组的代谢生物组网络药理学网络药理学

更多相关视频

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Electroacupuncture Combined with Chinese Medicine Ironing Therapy for Functional Constipation

Published on: July 5, 2024

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Drugs Affecting GI Tract Motility: Other Laxatives

Drugs Affecting GI Tract Motility: Other Laxatives

Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives

Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...